This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
The report finds that NCCPs rarely specify the funds that need to be committed or the spending that occurs in practice. When evidence of funding impact is...
Similarly, with a Republican majority in the US House and Senate, it is unknown what the legislative agenda for 2025 will look like and how the nation’s public...
